Category: CBDs
-
![Discover Wellness (WLNS.C) enters the $3.5 billion global CBD market with a lean mean business model]()
Discover Wellness (WLNS.C) enters the $3.5 billion global CBD market with a lean mean business model
“The contribution of this first 550,000 kg of high-CBD biomass from SG and the completion of the Strategic Alliance agreement is a significant first step in leveraging the combined resources under the Discover Wellness umbrella,” stated Peter Cheung, Interim CEO of WLNS,
-
![As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat]()
As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat
News this week that Canntab Therapeutics (PILL.C) received an Australian patent for their hard-pressed cannabis pill tech, to match those received earlier in North America, didn’t launch the stock into space. That’s understandable, to be honest, as North American investors have taken an eye off the island continent and its slow roll to weed legalization…
-
![Heritage Cannabis (CANN.C) Receives Health Canada Export License]()
Heritage Cannabis (CANN.C) Receives Health Canada Export License
Heritage Cannabis (CANN.C) has been granted an export license by Health Canada. The license will permit the Company to export cannabis products to Brazil marking the first-ever license granting the export of CBD products from Canada to Brazil. “We are very pleased to be the first cannabis company in Canada to be granted an export…
-
![Heritage Cannabis (CANN.C) Exceeds $1M in Weekly Revenue]()
Heritage Cannabis (CANN.C) Exceeds $1M in Weekly Revenue
Heritage Cannabis (CANN.C) achieved a weekly revenue exceeding $1 million during the second week of March, 2021. “This achievement is an exciting milestone for Heritage as we continue to develop and innovate new products within our already popular brands…while there is still much more work to be done to make this a consistent outcome, we…
-
Pure Extracts (PULL.C) looks to level up with dealers license application
At a time when many cannabis companies are enjoying bursts of investor interest, management at BC-based extractor Pure Extracts (PULL.C) must be getting frustrated as they roll out new contracts, new manufacturing lines, and advance in their pursuit of licensing that would allow them to break out into psychedelics. In essence, they’re hitting all the…
-
![Canntab Therapeutics (PILL.C) racks up revenue as CBD caplets shipped to Medipharm (LABS.T)]()
Canntab Therapeutics (PILL.C) racks up revenue as CBD caplets shipped to Medipharm (LABS.T)
Cannabis hard tablet IP holder Canntab Therapeutics (PILL.C) continues to send product to market, announcing Wednesday they’ve fulfilled 80% of their contract with Medipharm Labs (LABS.T), bringing in another half million dollars in revenue toward the $1.3 million deal announced last June. Orders under the agreement are a mix of Canntab’s proprietary instant release tablets…
-
Delic Holdings (DELC.C) acquires licensed psilocybin/cannabis lab, is doing legal shroom business
For a year, naysayers have dismissed the early stage shroom boom as being a pumpy bunch of pubco RTOs that won’t be able to do business legally for years. To be fair, there’s some basis to that dismissal. But only some. We’ve also been talking about how Delic Holdings (DELC.C) was an all-star team of…
-
![Pure Extracts (PULL.C) cuts a licensing deal with Taste-T, the maker of Fireball Cannabis Gummies]()
Pure Extracts (PULL.C) cuts a licensing deal with Taste-T, the maker of Fireball Cannabis Gummies
Included in the agreement is the delivery to Pure Extracts’ British Columbia facility of one of Taste-T’s custom built gummie-manufacturing machines, certified to Canadian standards.
-
Canntab (PILL.C) yeets another patent for hard-pressed, long release cannabis pills
I’ve made no secret of the fact that the Canadian cannabis market frequently annoys the hell out of me. What I want is for it to be a mature space that more and more adults are making use of, and that is free to innovate, free to be excellent, free to market itself properly, and…
-
![Xphyto’s (XPHY.C) lays out its ambitious Parkinson’s/Epilepsy/Depression/Multiple Sclerosis drug formulation strategy which includes heavy investment in psychedelic medicine]()
Xphyto’s (XPHY.C) lays out its ambitious Parkinson’s/Epilepsy/Depression/Multiple Sclerosis drug formulation strategy which includes heavy investment in psychedelic medicine
Xphyto describes itself as “a bioscience accelerator” “targeting growth through commercialization of its product pipeline”.
